PL3487475T3 - Formulacja miękkich analogów antycholinergicznych - Google Patents

Formulacja miękkich analogów antycholinergicznych

Info

Publication number
PL3487475T3
PL3487475T3 PL17831882.0T PL17831882T PL3487475T3 PL 3487475 T3 PL3487475 T3 PL 3487475T3 PL 17831882 T PL17831882 T PL 17831882T PL 3487475 T3 PL3487475 T3 PL 3487475T3
Authority
PL
Poland
Prior art keywords
formulation
soft anticholinergic
anticholinergic analogs
analogs
soft
Prior art date
Application number
PL17831882.0T
Other languages
English (en)
Inventor
Nicholas S. Bodor
John J. Koleng
David Angulo
Original Assignee
Bodor Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bodor Laboratories, Inc. filed Critical Bodor Laboratories, Inc.
Publication of PL3487475T3 publication Critical patent/PL3487475T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17831882.0T 2016-07-21 2017-07-20 Formulacja miękkich analogów antycholinergicznych PL3487475T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365037P 2016-07-21 2016-07-21
PCT/US2017/043106 WO2018017852A1 (en) 2016-07-21 2017-07-20 Formulation for soft anticholinergic analogs

Publications (1)

Publication Number Publication Date
PL3487475T3 true PL3487475T3 (pl) 2023-10-30

Family

ID=60989819

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17831882.0T PL3487475T3 (pl) 2016-07-21 2017-07-20 Formulacja miękkich analogów antycholinergicznych

Country Status (17)

Country Link
US (5) US11123325B2 (pl)
EP (2) EP3487475B1 (pl)
AU (2) AU2017298469B2 (pl)
BR (1) BR112019001081B1 (pl)
CA (1) CA3031361C (pl)
DK (1) DK3487475T3 (pl)
ES (1) ES2954308T3 (pl)
FI (1) FI3487475T3 (pl)
HU (1) HUE062905T2 (pl)
IL (2) IL264311B (pl)
MX (2) MX2019000812A (pl)
PH (1) PH12019500142A1 (pl)
PL (1) PL3487475T3 (pl)
PT (1) PT3487475T (pl)
TW (2) TWI719046B (pl)
WO (1) WO2018017852A1 (pl)
ZA (1) ZA201901060B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6513667B2 (ja) 2013-08-08 2019-05-15 ノヴァン,インコーポレイテッド 局所用組成物およびそれを使用する方法
US10322082B2 (en) 2014-07-11 2019-06-18 Novan, Inc. Topical antiviral compositions and methods of using the same
TWI719046B (zh) * 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑
US20210290536A1 (en) * 2018-07-24 2021-09-23 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound
WO2021177257A1 (ja) 2020-03-03 2021-09-10 科研製薬株式会社 原発性腋窩多汗症の治療方法、及びその医薬
CA3174550A1 (en) * 2020-03-03 2021-09-10 Kaken Pharmaceutical Co., Ltd. Medicament containing sofpironium bromide

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US242A (en) 1837-06-22 moseley
US5292530A (en) 1991-06-02 1994-03-08 Helene Curtis, Inc. Stable anhydrous topically-active composition and suspending agent therefor
US5232689A (en) 1990-12-21 1993-08-03 Dow Corning Corporation Translucent antiperspirant compositions
GB2280111B (en) * 1993-07-16 1997-05-07 Union Camp Corp Clear gel antiperpirant compositions
US5895644A (en) 1997-11-20 1999-04-20 Colgate-Palmolive Company Clear antiperspirant stick with dibenzylidene sorbitol and guar and process of making same
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
EP1239890B1 (en) * 1999-12-13 2004-11-10 Symrise GmbH & Co. KG Odor neutralizers
US6319491B1 (en) * 2000-04-11 2001-11-20 Michael B. Whipple Anti-sweat lotion
CA2461696A1 (en) 2001-09-26 2003-04-03 Alison B. Lukacsko Compositions and methods for inhibiting eccrine perspiration in humans
JP2003113392A (ja) * 2001-10-04 2003-04-18 Kiyomitsu Kawasaki 芳香・消臭組成物および該芳香・消臭組成物を含有する人体用芳香・消臭剤
US8252316B2 (en) 2002-05-03 2012-08-28 Purepharm Inc. Method of topically applying glycopyrrolate solution using absorbent pad to reduce sweating
BR0308051A (pt) * 2003-12-15 2005-09-06 Natura Cosmeticos Sa Composição base para preparação de formulações multifuncionais para o cuidado e proteção da pele e cabelo
US7087560B2 (en) 2004-10-25 2006-08-08 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Personal care composition with salts of dihydroxypropyltri(C1-C3 alkyl) ammonium monosubstituted polyols
US20060088496A1 (en) 2004-10-25 2006-04-27 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal care compositions with salts of hydroxypropyl trialkylammonium substituted mono-saccharide
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0428418D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
WO2006069998A2 (de) 2004-12-27 2006-07-06 Beiersdorf Ag Glycopyrrolat in kosmetischen zubereitungen
JP2007058971A (ja) 2005-08-24 2007-03-08 Alpine Electronics Inc 情報再生装置
ATE529399T1 (de) 2005-11-10 2011-11-15 Nicholas S Bodor Sanfte anticholinerge ester
WO2007059021A1 (en) 2005-11-10 2007-05-24 Bodor Nicholas S Soft anticholinergic zwitterions
US8071693B2 (en) 2006-06-22 2011-12-06 Sabic Innovative Plastics Ip B.V. Polysiloxane/polyimide copolymers and blends thereof
JP5371235B2 (ja) 2006-12-06 2013-12-18 ロート製薬株式会社 皮膚外用剤
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
WO2009051818A1 (en) 2007-10-18 2009-04-23 Stiefel Research Australia Pty Ltd Topical glycopyrrolate formulations
KR102050299B1 (ko) * 2013-03-15 2019-11-29 보도르 라보래토리즈, 인크. 다한증 치료용 항콜린성 글리코피롤레이트 에스테르
WO2015015446A1 (en) 2013-07-30 2015-02-05 Glaxosmithkline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
US20150259283A1 (en) * 2014-03-13 2015-09-17 Brickell Biotech, Inc. Formulation for soft anticholinergic analogs
WO2015138700A1 (en) * 2014-03-13 2015-09-17 Bodor Laboratories, Inc. Use of selected anticholinergic zwitterions
PL3325487T3 (pl) * 2015-07-21 2021-12-13 Bodor Laboratories, Inc. Preparat miękkich analogów przeciwcholinergicznych
TWI719046B (zh) * 2016-07-21 2021-02-21 美商波德實驗股份有限公司 軟性抗膽鹼類似物之製劑

Also Published As

Publication number Publication date
CA3031361A1 (en) 2018-01-25
BR112019001081A2 (pt) 2019-04-30
EP3487475A1 (en) 2019-05-29
US20190247362A1 (en) 2019-08-15
TWI719046B (zh) 2021-02-21
ZA201901060B (en) 2022-04-28
DK3487475T3 (da) 2023-09-11
AU2017298469A1 (en) 2019-02-21
PH12019500142A1 (en) 2019-07-29
IL264311B (en) 2022-08-01
US11052067B2 (en) 2021-07-06
US20200101044A1 (en) 2020-04-02
EP3487475B1 (en) 2023-06-07
AU2017298469B2 (en) 2023-02-02
AU2023202689B2 (en) 2024-08-01
MX2019000812A (es) 2019-06-20
AU2023202689A1 (en) 2023-05-18
BR112019001081B1 (pt) 2022-06-14
US10959983B2 (en) 2021-03-30
TW202131913A (zh) 2021-09-01
TWI767507B (zh) 2022-06-11
ES2954308T3 (es) 2023-11-21
US20210077459A1 (en) 2021-03-18
EP4218725A1 (en) 2023-08-02
MX2022009375A (es) 2022-09-02
PT3487475T (pt) 2023-09-05
IL264311A (en) 2019-02-28
IL295009A (en) 2022-09-01
WO2018017852A1 (en) 2018-01-25
EP3487475A4 (en) 2020-03-04
FI3487475T3 (fi) 2023-08-25
CA3031361C (en) 2024-02-27
US20220000839A1 (en) 2022-01-06
US20180021300A1 (en) 2018-01-25
HUE062905T2 (hu) 2023-12-28
US11123325B2 (en) 2021-09-21
TW201803561A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
ZA201607071B (en) Formulation for soft anticholinergic analogs
GB2551985B (en) Novel formulation
HK1253236A1 (zh) 軟性抗膽碱能藥類似物的製劑
ZA201901060B (en) Formulation for soft anticholinergic analogs
GB201513010D0 (en) Novel formulation
GB201619525D0 (en) Ophthalmic composition
GB201514758D0 (en) Formulation
IL273387A (en) Thylanstatin analogs
GB201608356D0 (en) Formulation
PL3173071T3 (pl) Formulacja maropitantu
SG10201504761YA (en) Composition for Markings
IL258295A (en) Fviii formulation
GB201521771D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201509891D0 (en) Formulation
GB201707615D0 (en) Formulation
PL3446682T3 (pl) Kompozycja okulistyczna
PL3559185T3 (pl) Preparat nabłyszczający
GB201609925D0 (en) Formulation
GB201602048D0 (en) Formulation
SG10201703749UA (en) Composition for Markings
GB201508527D0 (en) Novel formulation
GB201514014D0 (en) Formulation
GB201504662D0 (en) Formulation